TLC determination of griseofulvin in plasma and 6-demethylgriseofulvin in urine

Authors

  • Y. Garceau,

    1. Biopharmacy Section, Pharmacy Research and Development Division, Ayerst Laboratories, Inc., Rouses Point, NY 12979
    Search for more papers by this author
  • J. Brisson,

    1. Biopharmacy Section, Pharmacy Research and Development Division, Ayerst Laboratories, Inc., Rouses Point, NY 12979
    Search for more papers by this author
  • I. Davis,

    1. Biopharmacy Section, Pharmacy Research and Development Division, Ayerst Laboratories, Inc., Rouses Point, NY 12979
    Search for more papers by this author
  • R. L. Deangelis,

    1. Biopharmacy Section, Pharmacy Research and Development Division, Ayerst Laboratories, Inc., Rouses Point, NY 12979
    Current affiliation:
    1. Wellcome Research Laboratories, Research Triangle Park, NC 27709
    Search for more papers by this author
  • J. Hasegawa

    Corresponding author
    1. Biopharmacy Section, Pharmacy Research and Development Division, Ayerst Laboratories, Inc., Rouses Point, NY 12979
    • Biopharmacy Section, Pharmacy Research and Development Division, Ayerst Laboratories, Inc., Rouses Point, NY 12979
    Search for more papers by this author

Abstract

Fluorometric TLC procedures are described for the determination of griseofulvin in human plasma and 6-demethylgriseofulvin in human urine. Griseofulvin is extracted from plasma with ether, and its metabolite, 6-demethylgriseofulvin, is extracted from urine with benzene. Both compounds are subjected to TLC on silica gel plates. The plates are scanned using the fluorescent mode of a spectrodensitometer. For griseofulvin, the quantitation limit is 20 ng/ml of plasma and the recovery is 100%; for 6-demethylgriseofulvin, the limit is 1 μ/ml of urine and the recovery is 96%. The methods were used to determine the plasma levels of griseofulvin and the amount of 6-demethylgriseofulvin excreted in the urine of human volunteers after a single oral dose of griseofulvin.

Ancillary